Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06931405 · ClinicalTrials.gov registry record · Phase 2
Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)
A Phase 2 study of Chronic Spontaneous Urticaria and Chronic Inducible Urticaria, sponsored by Blueprint Medicines Corporation.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
- 20
- Study locations
NCT06931405: Recruiting Phase 2 study of Chronic Spontaneous Urticaria and Chronic Inducible Urticaria, sponsored by Blueprint Medicines Corporation.
NCT06931405 is a Phase 2 study of Chronic Spontaneous Urticaria and Chronic Inducible Urticaria that is actively recruiting participants, run by Blueprint Medicines Corporation. The registered enrollment target is 105 participants, below the 1,421-participant average among 18 other Chronic Spontaneous Urticaria trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06931405, a Phase 2 study of Chronic Spontaneous Urticaria and Chronic Inducible Urticaria, is actively recruiting participants, sponsored by Blueprint Medicines Corporation.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a 2-part, proof-of-concept study to be conducted globally, designed to evaluate the safety, tolerability, clinical activity, pharmacokinetics, and pharmacodynamics of BLU-808, a wild type KIT inhibitor, in participants with CIndU (Part A) or CSU (Part B).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BLU-808
Study Locations (20)
California
- Modena Allergy & Asthma Clinical Research - La Jolla - La Jolla
- Allergy & Asthma Associates of Southern California - Laguna Niguel
- Allergy & Asthma Medical Group and Research Center - San Diego
Indiana
- Dawes Fretzin Clinical Research Group, LLC - Indianapolis
- Southern Indiana Clinical Trials - New Albany
- The Indiana Clinical Trials Center - Plainfield
Maryland
- Johns Hopkins University - Baltimore
- Institute For Asthma & Allergy - Wheaton
- Chesapeake Clinical Research - White Marsh
Florida
- Allergy Affiliates Inc. - Bradenton
- University of South Florida - Tampa
Alabama
- Allervie Clinical Research - Birmingham
Arkansas
- Acuro Research, Inc. - Little Rock
Idaho
- Treasure Valley Medical Research - Boise
Illinois
- Endeavor Health - Northbrook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2025-05-28 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
What NCT06931405 shows while recruiting
NCT06931405 is an interventional study that assigns participants to a tested intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap, below the 1,421-participant average among 18 other Chronic Spontaneous Urticaria trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Chronic Spontaneous Urticaria appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06931405 names 20 study sites across 13 states, led by California, Indiana, Maryland.
Frequently Asked Questions
What is clinical trial NCT06931405 about?
NCT06931405 is a clinical study titled "Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)". This is a 2-part, proof-of-concept study to be conducted globally, designed to evaluate the safety, tolerability, clinical activity, pharmacokinetics, and pharmacodynamics of BLU-808, a wild type KIT inhibitor, in participants with CIndU (Part A) or CSU (Part B).
What is the current status of trial NCT06931405?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2025-05-28. Estimated completion is 2026-12-31.
What conditions does trial NCT06931405 study?
This clinical trial studies the following conditions: Chronic Spontaneous Urticaria, Chronic Inducible Urticaria.
What interventions are being tested in trial NCT06931405?
The interventions under investigation include: Placebo (DRUG), BLU-808 (DRUG).
Who is sponsoring clinical trial NCT06931405?
This trial is sponsored by Blueprint Medicines Corporation, which has 24 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06931405 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Florida, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Spontaneous Urticaria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06931405's enrollment target sits among peer trials
105 15th of 18 higher than 4 of 18 other Chronic Spontaneous Urticaria trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Spontaneous Urticaria trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)
RECRUITING · Phase 2
-
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
RECRUITING · Phase 2
-
An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU
COMPLETED · Phase 2
-
Remibrutinib in Real-world Clinical Practice - a US Sub-study
RECRUITING
-
Remibrutinib in Real-world Clinical Practice
RECRUITING
-
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03372317 · 105 participants
Tau PET in Imaging and Cognition: Healthy Adults From 55-90
- NCT04253964 · 105 participants · Phase 2
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
- NCT04742452 · 105 participants · NA
Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears
- NCT04875429 · 105 participants · NA
Zenith® Fenestrated+ Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI